Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2010
04/01/2010US20100080804 Methods of treating inflammatory disorders of the lungs
04/01/2010US20100080799 Wstf regulates the dna damage response of h2a.x via novel tyrosine kinase activity
04/01/2010US20100080795 Biodegradable thermogelling polymer
04/01/2010US20100080788 Alginate and alginate lyase compositions and methods of use
04/01/2010US20100080786 Phenyl or Pyridinyl Substituted Indazoles Derivatives
04/01/2010US20100080785 Dried formulations
04/01/2010US20100080776 Method of enhancing an immune response
04/01/2010US20100080773 Orally Bioavailable Lipid-Based Constructs
04/01/2010US20100080772 Hepatitis C Virus Inhibitors
04/01/2010US20100080771 Hepatitis C Virus Inhibitors
04/01/2010US20100080770 Hepatitis C Virus Inhibitors
04/01/2010US20100080769 Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies
04/01/2010US20100080768 Compositions and Methods for the Treatment of Inflammatory Dermatosis and Other Pathological Conditions of the Skin
04/01/2010US20100080764 Skin Treatment Systems
04/01/2010US20100080762 Skin care composition
04/01/2010US20100080756 Methods for protecting and regenerating bone marrow using cxcr3 agonists and antagonists
04/01/2010DE202010001237U1 Kombination aus Tramadol und Acetaminophen als Brausetablette Combination of tramadol and acetaminophen effervescent tablet
04/01/2010DE19943491B4 Verbesserte Komprimate Improved compressed
04/01/2010CA2775660A1 Device for photodynamical therapy of cancer
04/01/2010CA2775370A1 Nitric oxide releasing amino acid ester compound, composition and method of use
04/01/2010CA2739375A1 Derivatives of 1-amino-2-cyclobutylethylboronic acid
04/01/2010CA2739170A1 Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
04/01/2010CA2738878A1 Selective estrogen receptor modulator for the treatment of osteoarthritis
04/01/2010CA2738819A1 Bloat therapeutic agent for a ruminant
04/01/2010CA2738809A1 Quinazolinone, quinolone and related analogs as sirtuin modulators
04/01/2010CA2738794A1 Chromenone analogs as sirtuin modulators
04/01/2010CA2738769A1 Vaccine adjuvants
04/01/2010CA2738755A1 Individual 5-fluorouracile dose optimization in folfiri treatment
04/01/2010CA2738605A1 Composition and method for treatment of preterm labor
04/01/2010CA2738598A1 Composition for treating disease
04/01/2010CA2738490A1 Bioadhesive constructs
04/01/2010CA2738477A1 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis
04/01/2010CA2738468A1 Topical formulations for treatment of neuropathy
04/01/2010CA2738448A1 New chemical compounds
04/01/2010CA2738429A1 Heterocyclic kinase inhibitors
04/01/2010CA2738392A1 Process for the preparation of rotigotine
04/01/2010CA2738254A1 Oxazolobenzimidazole derivatives
04/01/2010CA2738236A1 Process for making quinolone compounds
04/01/2010CA2738197A1 Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
04/01/2010CA2738147A1 Solid pharmaceutical composition
04/01/2010CA2738127A1 Novel crystal form of calcium 3-acetylaminopropane-1-sulfonate
04/01/2010CA2738083A1 1h-benzimidazole-5-carboxamides as anti-inflammatory agents
04/01/2010CA2738081A1 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
04/01/2010CA2738078A1 Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
04/01/2010CA2738025A1 Protease inhibitors
04/01/2010CA2738023A1 Protease inhibitors
04/01/2010CA2737958A1 Hepatitis c inhibitor compounds
04/01/2010CA2737948A1 Host cell kinases as targets for antiviral therapies against hcv infection
04/01/2010CA2737944A1 Reducing astringency in compositions containing phenolic compounds
04/01/2010CA2737941A1 Selective seprase inhibitors
04/01/2010CA2737912A1 Fused ring thiophene dyes for imaging and therapy
04/01/2010CA2737839A1 3h-imidazo [4, 5-c] pyridine-6-carboxamides as anti-inflammatory agents
04/01/2010CA2737739A1 Heteroaryl antagonists of prostaglandin d2 receptors
04/01/2010CA2737694A1 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
04/01/2010CA2737645A1 Compounds which selectively modulate the cb2 receptor
04/01/2010CA2737639A1 Compounds which selectively modulate the cb2 receptor
04/01/2010CA2737618A1 Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
04/01/2010CA2737552A1 3h-imidazo [4,5-b] pyridine-6-carboxamides as anti-inflammatory agents
04/01/2010CA2737472A1 Azaindazole compounds as ccr1 receptor antagonists
04/01/2010CA2737384A1 1h-benzimidazole-5-carboxamides as anti-inflammatory agents
04/01/2010CA2737264A1 Polymorphic form of calcium acamprosate
04/01/2010CA2737252A1 Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors
04/01/2010CA2737077A1 Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
04/01/2010CA2737031A1 Indole and indoline derivatives and methods of use thereof
04/01/2010CA2736880A1 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
04/01/2010CA2736724A1 Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors
04/01/2010CA2736545A1 Dosage units of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
04/01/2010CA2736539A1 Compound for local deletion of tumors
04/01/2010CA2736472A1 Pyrine or pyrazine derivatives for treating hcv
04/01/2010CA2736434A1 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
04/01/2010CA2736285A1 Agent for preventing and/or treating functional gastrointestinal disorder
04/01/2010CA2736259A1 Galenical formulation comprising aliskiren and process for its preparation by melt extrusion granulation
04/01/2010CA2735899A1 Liquid formulations of bendamustine
04/01/2010CA2735886A1 Indazole or 4,5,6,7-tetrahydro-indazole derivatives
04/01/2010CA2734472A1 2-[1h-benzimidazol-2(3h)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3h)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors
04/01/2010CA2730002A1 Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors
04/01/2010CA2725574A1 Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
04/01/2010CA2723086A1 Antiviral drugs for treatment of arenavirus infection
03/2010
03/31/2010EP2169060A1 Novel polypeptide useful for diagnosis and treatment of cancer
03/31/2010EP2169059A1 Means and methods for counteracting, preventing and/or determining fibrosis or a risk of fibrosis
03/31/2010EP2169057A1 Double-stranded rna originating in lactic acid bacterium
03/31/2010EP2168992A1 Crosslinked polyallylamine or acid addition salt thereof, and use thereof for medical purposes
03/31/2010EP2168973A1 Nucleic acid ligand complexes
03/31/2010EP2168972A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity
03/31/2010EP2168969A2 Racemization and Enantiomer Separation of Clopidogrel
03/31/2010EP2168968A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
03/31/2010EP2168966A1 Bicycloaniline derivative
03/31/2010EP2168965A1 Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
03/31/2010EP2168964A1 Azaindole-indole coupled derivatives, preparation methods and uses thereof
03/31/2010EP2168962A2 Phenylacetamides and their use as glucokinase modulators
03/31/2010EP2168960A1 Pyrazolone derivative and pde inhibitor containing the same as active ingredient
03/31/2010EP2168959A1 Pyridazinone derivative and pde inhibitor containing the same as active ingredient
03/31/2010EP2168958A1 Isoindole-Imide Compounds, Compositions And Uses Thereof
03/31/2010EP2168957A2 Alkyl-substituted tetrahydropyranes as aromatic materials
03/31/2010EP2168955A1 Sleep-improving agent
03/31/2010EP2168954A1 Cysteine proteases inhibitors
03/31/2010EP2168952A1 Morpholine derivative
03/31/2010EP2168951A1 Azolylmethylenehydrazine derivative and use thereof
03/31/2010EP2168950A1 Inhibitor of the differentiation of t cells into th1 cells
03/31/2010EP2168948A1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
1 ... 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 ... 7860